Gary Richardson

Projects

Projects per year 2018 2020 2021 2022 2023 2027

• 2 Not started
• 18 Active
• 46 Finished

Projects per year

Search results

• Active

  A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Bhave, P. (Primary Chief Investigator (PCI))

  8/10/24 → 7/10/26

  Project: Research

• A Phase 3, Randomized, placebo-controlled, double-blind, Multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with P53wild-type, advanced or recurrent endometrial carcinoma

  Richardson, G. (Primary Chief Investigator (PCI))

  21/01/24 → 21/01/26

  Project: Research

• First-in-Human, Phase 1 Study of AMT-253, an Anti-MUC18 Antibody- Drug Conjugate, in Patients with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  24/10/23 → 23/10/25

  Project: Research

• A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  17/10/23 → 16/10/25

  Project: Research

• A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors.

  Richardson, G. (Primary Chief Investigator (PCI))

  13/10/23 → 12/10/25

  Project: Research

• First-in-Human, Phase 1 Study of AMT-116, an AntiCD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  14/09/23 → 15/09/25

  Project: Research

• A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of RX108-A Tablet in Patients with Locally Advanced or Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  10/09/23 → 9/09/25

  Project: Research

• A Phase 1b study to evaluate HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations

  Richardson, G. (Primary Chief Investigator (PCI))

  23/08/23 → 22/08/25

  Project: Research

• A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  25/07/23 → 25/07/26

  Project: Research

• Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinumbased chemotherapy plus bevacizumab (GLORIOSA)

  Richardson, G. (Primary Chief Investigator (PCI))

  19/07/23 → 18/07/26

  Project: Research

• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6- positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  Richardson, G. (Primary Chief Investigator (PCI))

  4/07/23 → 3/07/25

  Project: Research

• Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  Richardson, G. (Primary Chief Investigator (PCI))

  15/05/23 → 14/05/26

  Project: Research

• A Phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280 in patients with unresectable locally advanced or metastatic cancer.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  2/05/22 → 31/12/27

  Project: Research

• A Phase 1 study of SRF617 in patients with advanced solid tumors.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  1/04/22 → 31/12/25

  Project: Research

• A Phase 1 / 2 Study of HLX301, A Recombinant Humanized Anti-PDL1 and Anti-TIGIT Bispecific Antibody, in Patients with Locally Advanced or Metastatic Solid Tumours.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  1/03/22 → 31/12/25

  Project: Research

• A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in Combination with an Anti-PD-1 Antibody in Subjects with Advanced Solid Tumours.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  24/02/22 → 31/12/25

  Project: Research

• Phase 2 study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumours [WO42178] [BOUQUET]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  15/09/21 → 31/12/27

  Project: Research

• Measuring adherence to best practice guidelines for the management of ovarian cancer in Australia to determine the extent to which variation in care influences clinical and patient-reported outcomes

  Zalcberg, J. (Primary Chief Investigator (PCI)), Rome, R. (Chief Investigator (CI)), Antony, J. (Chief Investigator (CI)), Schofield, P. E. (Chief Investigator (CI)), Brand, A. H. (Chief Investigator (CI)), Richardson, G. (Chief Investigator (CI)), Farrell, R. (Chief Investigator (CI)), Evans, S. (Chief Investigator (CI)), Hegarty, S. (Chief Investigator (CI)) & Earnest, A. (Chief Investigator (CI))

  Department of Health and Aged Care (Australia)

  1/06/20 → 30/11/25

  Project: Research

• Not started

  A Phase 1/2, first-in-human, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics and efficacy of a trispecific EGFR/cMET antibody GB263T in subjects with advanced non-small cell lung cancer (NSCLC) and other solid tumors [GB263T-FIH001].

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  Project: Research

• A Phase 1/2, Open-label Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumours with a KRAS p.G12C Mutation [D3S-001-100].

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  Project: Research

• Finished

  A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers

  Richardson, G. (Primary Chief Investigator (PCI))

  13/09/23 → 13/09/23

  Project: Research

• Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First -In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  24/02/23 → 24/02/25

  Project: Research

• Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  24/02/23 → 24/02/24

  Project: Research

• There is also an updated standard indemnity where the study Name has been updated to A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 Conditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  7/12/22 → 7/12/24

  Project: Research

• Generation of a pre-clinical testing platform to enable selection of personalised drug treatments for patients with BRAF-mutant Colorectal cancer (CRC)

  Abud, H. (Primary Chief Investigator (PCI)), Engel, R. (Chief Investigator (CI)), McMurrick, P. (Chief Investigator (CI)), Shapiro, J. (Chief Investigator (CI)), Archer, S. (Chief Investigator (CI)) & Richardson, G. (Chief Investigator (CI))

  1/11/22 → 31/01/24

  Project: Research

• A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  17/03/22 → 31/12/24

  Project: Research

• Phase 1-2 study investigating, safety, tolerability, pharmacokinetics and preliminary antitumor activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in patients with advanced solid tumours.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  9/03/22 → 31/12/24

  Project: Research

• A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  18/02/22 → 1/12/24

  Project: Research

• PICCOLO: A Phase 2, single arm study of Mirvetuximab Soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  11/02/22 → 31/12/24

  Project: Research

• A first in human Phase 1/2 open-label, multicentre, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  1/02/22 → 30/11/24

  Project: Research

• A multi-center, single-arm and open-label Phase Ib/II study exploring the safety/tolerability, pharmacokinetics and efficacy of GFH018 in combination with Toripalimab in the treatment of patients with advanced solid tumours

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  8/12/21 → 31/12/24

  Project: Research

• Phase 1 b/2a study investigating ATX-101 in combination with platinum-based chemotherapy in platinum-sensitive, recurrent ovarian, fallopian tube and primary peritoneal cancer

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  22/11/21 → 31/12/24

  Project: Research

• An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  20/11/21 → 31/12/24

  Project: Research

• A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  21/10/21 → 31/12/24

  Project: Research

• A Phase I, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  27/09/21 → 31/12/24

  Project: Research

• A Phase 1 First in Human, Multicentre, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of CCX559 in Subjects with Solid Tumors [CL001_559]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  1/09/21 → 31/12/24

  Project: Research

• A Phase 1, First-in-Human, Open-Label, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects with Advanaced Tumours

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  14/07/21 → 31/12/24

  Project: Research

• A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma [ZN-c3-004]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  18/05/21 → 31/12/24

  Project: Research

• A randomised, multicentre, double-blind, placebo-controlled, phase III study of first line Carboplatin and Paclitaxel in combination with Durvalumab, followed by maintenance durvalumab with or without Olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer [DUO-E]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  14/04/21 → 31/12/24

  Project: Research

• A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Hoon, L. L. (Project Manager)

  11/03/21 → 31/12/24

  Project: Research

• A First-in-Human (FIH), Open-Label, Phase I Dose Escalation and Expansion Study of ADG126, ADG126 in Combination with Toripalimab, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  11/03/21 → 31/12/24

  Project: Research

• A randomised, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with EGFR Exon 20ins mutated locally advanced or metastatic non-small cell lung cancer (PAPILLON)

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  1/03/21 → 31/12/24

  Project: Research

• A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [MARIPOSA].

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  26/02/21 → 31/12/23

  Project: Research

• A phase 1/2, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of D-1553 in subjects with advanced or metastatic solid tumors with KRasG12C mutation

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  20/01/21 → 31/12/24

  Project: Research

• Treatment for a poor prognosis subset of estrogen receptor breast cancers.

  Mitchell, C. (Primary Chief Investigator (PCI)), McLean, C. (Chief Investigator (CI)), Loi, S. (Associate Investigator (AI)) & Richardson, G. (Associate Investigator (AI))

  1/01/21 → 31/12/23

  Project: Research

• A phase 1, first in human, multicenter, open-label, study of GQ1001, a HER2 targeted antibody-drug conjugate administered intravenously in adult patients with HER2 - positive advanced solid tumors [GQCT001/GQ1001X2101]

  Richardson, G. (Primary Chief Investigator (PCI))

  1/12/20 → 31/12/24

  Project: Research

• MIRASOL: A randomised, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  30/11/20 → 31/12/24

  Project: Research

• A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY OR BEVACIZUMAB IN SUBJECTS WITH OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  22/10/20 → 31/12/22

  Project: Research

• An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter)

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  14/10/20 → 31/12/24

  Project: Research

• A phase 1, open-label, dose escalation study of ADG116 in patients with advanced/metastatic solid tumors [ADG116-1003].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  24/09/20 → 31/12/23

  Project: Research